Barclays initiated coverage on TransMedics Group (TMDX) on Wednesday, assigning the medical technology company an "overweight" rating. The bank set a price target of $120.00 per share. This target suggests a substantial potential upside from the stock's previous closing price.
Barclays issued the new rating as part of its broader positive view on the medical suppliers and devices sector.
The firm noted recent sector underperformance creates an opportunity to invest in high-quality companies at attractive valuations. Barclays anticipates stabilizing fundamentals in 2027 will boost investor sentiment.
Following the announcement, shares of TransMedics traded higher.